Aldosterone, c-reactive protein, and plasma b-type natriuretic peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components : Findings from the jackson heart study

Diabetes Care

Volumn 36, Issue 10, 2013, Pages 3084-3092

  Musani, Solomon K ^a   Vasan, Ramachandran S ^b   Bidulescu, Aurelian ^c   Liu, Jiankang ^a   Xanthakis, Vanessa ^b   Sims, Mario ^a   Gawalapu, Ravi K ^d   Samdarshi, Tandaw E ^a   Steffes, Michael ^e   Taylor, Herman A ^a   Fox, Ervin R ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

^d JACKSON STATE UNIVERSITY   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; ENDOTHELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROCORTISONE; LEPTIN; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; ALDOSTERONE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; AGED; ALDOSTERONE; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN;

EID: 84891840701     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2562     Document Type: Article

References (40)

1. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47
2. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-369
3. Olsen MH, Hansen TW, Christensen MK, et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005;46: 660-666
4. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004;110:1507-1512
5. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004; 291:1978-1986
6. Stiefel P, Vallejo-Vaz AJ, Garca Morillo S, Villar J. Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome. Int J Hypertens 2011;2011: 685238
7. Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis 2010;52:401-409
8. Fox ER, Musani SK, Singh P, et al. Association of plasma B-type natriuretic peptide concentrations with longitudinal blood pressure tracking in African Americans: findings from the Jackson Heart Study. Hypertension 2013;61:48-54
9. Ingelsson E, Pencina MJ, Tofler GH, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 2007;116:984-992
10. Reilly MP, Wolfe ML, Rhodes T, Girman C,Mehta N, Rader DJ.Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 2004;110:803-809
11. St-Onge MP, Janssen I, Heymsfield SB. Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual. Diabetes Care 2004;27:2222-2228
12. Fuqua SR, Wyatt SB, Andrew ME, et al. Recruiting African-American research participation in the Jackson Heart Study: methods, response rates, and sample description. Ethn Dis 2005;15(Suppl. 6): S6-S18, 29
13. Day C. Metabolic syndrome, or What you will: definitions and epidemiology. Diab Vasc Dis Res 2007;4:32-38
14. Ganser GH, Hewett P. An accurate substitution method for analyzing censored data. J Occup Environ Hyg 2010;7:233-244
15. Meigs JB, Wilson PW, Nathan DM, D'Agostino RB Sr, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and FraminghamOffspring Studies. Diabetes 2003;52:2160-2167
16. Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006;48:239-245
17. Kidambi S, Kotchen JM, Grim CE, et al. Association of adrenal steroids with hypertension and themetabolic syndrome in blacks. Hypertension 2007;49:704-711
18. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006;47:312-318
19. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004;351:33-41
20. Sowers JR, Bakris GL, Black HR, Giles TD. The cardiometabolic syndrome and calcium channel blocker combination drugs. J Cardiometab Syndr 2007;2:207-212
21. Stas S, Whaley-Connell AT, Sowers JR. Aldosterone and hypertension in the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2008;10:94-96
22. Wehling M, Christ M, Theisen K. Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action. Am J Physiol 1992;263:E974-E979
23. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009;150: 776-783
24. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008;51:161-167
25. Funder JW. The nongenomic actions of aldosterone. Endocr Rev 2005;26:313-321
26. Du Clos TW. Function of C-reactive protein. Ann Med 2000;32:274-278
27. AlbertMA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol 2004;93:1238-1242
28. Kim CX, Bailey KR, Klee GG, et al. Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study. PLoS ONE 2010;5: e9065
29. Fox ER, Benjamin EJ, Sarpong DF, et al. Epidemiology, heritability, and genetic linkage of C-reactive protein in African Americans (from the Jackson Heart Study). Am J Cardiol 2008;102:835-841
30. Maachi M, Piéroni L, Bruckert E, et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord 2004;28:993-997
31. Feingold KR, Staprans I, Memon RA, et al. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res 1992; 33:1765-1776
32. Licata G, Volpe M, Scaglione R, Rubattu S. Salt-regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 1994;23(Suppl.):I20-I24
33. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007;115:1345-1353
34. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005;112:2163-2168
35. Li WY, Chiu FC, Chien YF, Lin JW, Hwang JJ. Association of amino-terminal pro-brain natriuretic peptide with metabolic syndrome. Intern Med 2011;50: 1143-1147
36. Houben AJ, van der Zander K, de Leeuw PW. Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology. Fundam Clin Pharmacol 2005;19:411-419
37. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339:321-328
38. Richards AM. Natriuretic peptides: update on Peptide release, bioactivity, and clinical use. Hypertension 2007;50:25-30
39. Verspohl EJ, Bernemann IK. Atrial natriuretic peptide (ANP)-induced inhibition of glucagon secretion: mechanism of action in isolated rat pancreatic islets. Peptides 1996;17:1023-1029
40. Birkenfeld AL, Boschmann M, Moro C, et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab 2005;90:3622-3628